Market Place
Sourcing Support
Gain Therapeutics to Present Poster at IAPRD 2025 Congress
30 Apr 2025 //
GLOBENEWSWIRE
Gain`s Preclinical Data & Design of Phase 1b Study of GT-02287
10 Apr 2025 //
GLOBENEWSWIRE
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
28 Mar 2025 //
GLOBENEWSWIRE
Gain Therapeutics Reports Q4 and Year-End 2024 Financials Result
27 Mar 2025 //
GLOBENEWSWIRE
Gain Therapeutics Doses First Participant in GT-02287 Trial
14 Mar 2025 //
ACCESSWIRE
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
06 Mar 2025 //
GLOBENEWSWIRE
Gain Therapeutics CEO Gene Mack Issues Shareholder Update
06 Feb 2025 //
GLOBENEWSWIRE
Gain Therapeutics To Participate in Upcoming Investor Conferences
05 Feb 2025 //
GLOBENEWSWIRE
Gain Therapeutics Forms Advisory Board For Lead Drug GT-02287
08 Jan 2025 //
GLOBENEWSWIRE
Gain Therapeutics Names Gene Mack As CEO And Director
07 Jan 2025 //
GLOBENEWSWIRE
Gain Therapeutics Initiates Ph 1b Trial for GT-02287 in Parkinson’s
23 Dec 2024 //
GLOBENEWSWIRE
Gain Therapeutics To Present At Biotech Showcase 2025
11 Dec 2024 //
GLOBENEWSWIRE
Gain Therapeutics Reports Financial Results for Q3 2024 & Update
14 Nov 2024 //
GLOBENEWSWIRE
Gain Therapeutics Presents Data on DDR2 Inhibitors at EORTC
23 Oct 2024 //
GLOBENEWSWIRE
Gain Therapeutics Announces Presentation At EORTC-NCI-AACR Symposium
15 Oct 2024 //
GLOBENEWSWIRE
Gain To Present At Fox Foundation`s Parkinson`s Conference
09 Oct 2024 //
GLOBENEWSWIRE
Gain Therapeutics Presents GT-02287 Data At Neuroscience 2024
07 Oct 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Participate at Upcoming Investor Conferences
03 Oct 2024 //
GLOBENEWSWIRE
Gain Therapeutics Presents GT-02287 Data At Parkinson`s Congress
30 Sep 2024 //
GLOBENEWSWIRE
Gain Therapeutics To Host Webinar On GT-02287 Study Results
26 Sep 2024 //
GLOBENEWSWIRE
Gain Therapeutics To Present GT-02287 Data At Neuroscience 2024
19 Sep 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Attend H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Gain Reports Phase 1 Win For Parkinson`s Drug
30 Aug 2024 //
FIERCE BIOTECH
Gain Therapeutics Announces Positive Phase 1 Results for GT-02287 in Parkinson’s
29 Aug 2024 //
GLOBENEWSWIRE
Gain Therapeutics Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
01 Aug 2024 //
GLOBENEWSWIRE
Gain Therapeutics Completes Dosing In Phase 1 MAD Study For Parkinson`s
09 Jul 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
28 Jun 2024 //
GLOBENEWSWIRE
Gain Presents GT-02287 Data at FENS Forum 2024 Improvements in Cognitive
27 Jun 2024 //
GLOBENEWSWIRE
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
27 Jun 2024 //
GLOBENEWSWIRE
Gain to Present at H.C. Wainwright Neuro Perspectives Virtual Conference
25 Jun 2024 //
GLOBENEWSWIRE
Gain Therapeutics Prices $11M Public Offering
13 Jun 2024 //
GLOBENEWSWIRE
Gain Therapeutics Poster On Pipeline At FENS Forum 2024
30 May 2024 //
GLOBENEWSWIRE
Gain Therapeutics Reports Q1 2024 Results, Corporate Update
14 May 2024 //
GLOBENEWSWIRE
Gain`s GT-02287 Shows Positive Phase 1 Parkinson`s Results
24 Apr 2024 //
GLOBENEWSWIRE
Gain Appoints of Gene Mack as CFO
08 Apr 2024 //
GLOBENEWSWIRE
Gain Therapeutics Strengthens Team and Appoints Jonas as Chief Medical Officer
01 Apr 2024 //
GLOBENEWSWIRE
Gain Therapeutics Reports Financial Results for Year End 2023
26 Mar 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Present at Public Ventures Discovery Day
15 Mar 2024 //
GLOBENEWSWIRE
Gain Therapeutics Presents Data at the AD/PD 2024 Conference
05 Mar 2024 //
GLOBENEWSWIRE
Gain Therapeutics Announces the Initiation of Phase 1 Trial of GT-02287
27 Feb 2024 //
GLOBENEWSWIRE
Gain Therapeutics Announces 2024 R&D Update on Parkinson™s Disease
14 Feb 2024 //
GLOBENEWSWIRE
Gain Therapeutics GT-02287 Completely Restores Motor Function in Mouse Models
06 Feb 2024 //
GLOBENEWSWIRE
Gain`s clinical Parkinson`s drug restores motor function in mice
06 Feb 2024 //
FIERCE BIOTECH
Gain Therapeutics™ CEO Matthias Alder Issues Letter to Shareholders
31 Jan 2024 //
GLOBENEWSWIRE
Gain Therapeutics Announces Acceptance of Abstract for Platform Presentation
02 Jan 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Participate in FORCE Family Office Event
04 Dec 2023 //
GLOBENEWSWIRE
Gain Therapeutics Announces Data Showing Restoration of Enzymatic Function
01 Dec 2023 //
GLOBENEWSWIRE
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
29 Nov 2023 //
GLOBENEWSWIRE
Gain Therapeutics Announces Closing of $10.1 Million Public Offering
24 Nov 2023 //
GLOBENEWSWIRE
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering
21 Nov 2023 //
GLOBENEWSWIRE
Gain Therapeutics Announces Proposed Public Offering
20 Nov 2023 //
GLOBENEWSWIRE
Gain Therapeutics Announces Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Gain Announces Dosing of First Two Subjects in Phase 1 Trial of GT-02287
04 Oct 2023 //
GLOBENEWSWIRE
Gain Therapeutics to Participate at Cantor Fitzgerald Healthcare Conference 2023
25 Sep 2023 //
GLOBENEWSWIRE
Gain to Present at the Cambridge Healthtech Institute™s 2nd Annual Conference
20 Sep 2023 //
GLOBENEWSWIRE
Gain Therapeutics Receives Approval to Commence Phase 1 Study of GT-02287
12 Sep 2023 //
GLOBENEWSWIRE
Gain Presents Preclinical Data of Plasma Neurodegeneration Biomarker NfL
28 Aug 2023 //
GLOBENEWSWIRE
Gain Therapeutics Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Gain Therapeutics Announces Acceptance of Abstract for Presentation
07 Aug 2023 //
GLOBENEWSWIRE
